Lyumjev ® ▼ (insulin lispro)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Lyumjev® ▼ (insulin lispro): Use in Patients With COVID-19 (Coronavirus disease 2019)

The use of Lyumjev in patients with COVID-19 (coronavirus disease 2019) has not been studied.

Use of Lyumjev in Patients With COVID-19

COVID-19 is an infectious respiratory disease caused by new variations of the virus SARS-CoV-2, previously referred to as "2019 novel coronavirus."1,2

Lilly has not studied the use of Lyumjev in patients with COVID-19 nor in patients at risk of contracting COVID-19.

Clinicians should use their clinical judgment in determining the most appropriate approach in treating a patient with Lyumjev who has been exposed to or has confirmed or suspected COVID-19.

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to


1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 18, 2020.

2. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. Published online March 3, 2020.

3. Coronavirus disease (COVID-19) outbreak. World Health Organization Europe. Accessed March 20, 2020.

4. International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. Accessed March 18, 2020

5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020.


COVID-19 = coronavirus disease 2019

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

URLi = ultra rapid lispro

EU WHO = World Health Organization (European regional office)

IDF = International Diabetes Federation

ECDC = European Centre for Disease Prevention and Control

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: 18 March 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request